COMP <GO>
RGEN vs TWST // OPERATING MARGIN
Repligen Corporation (NASDAQ) VS. Twist Bioscience Corporation (NASDAQ) • 15-METRIC TALLY: RGEN 6
— TWST 5
▲ OPERATING MARGIN LEADER: RGEN
LAST: $172.95 (-2.25%) • MKT CAP: $10.03B
operating-margins
1.80%
LAST: $129.04 (-15.54%) • MKT CAP: $10.13B
operating-margins
-4.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. TWST)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | TWST | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.20% | 94.20% | -6.00 | TWST | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | -11.70% | +14.00 | RGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | -0.66% | +1.54 | RGEN | /fcf-yield <GO> |
| Operating Margin ACTIVE | 1.80% | -4.20% | +6.00 | RGEN | /operating-margins <GO> |
| Net Profit Margin | 1.60% | -2.40% | +4.00 | RGEN | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 16.50% | -19.80 | TWST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 26.00 | -16.69 | TWST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | RGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 48.4 | -0.40 | TWST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.98 | +0.06 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 21.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.03B | $10.13B | -$98.3M | TWST | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | TWST REV | RGEN GROSS % | TWST GROSS % | RGEN FCF | TWST FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $154.5M | $381.5M | — | — | $93.9M | -$75.6M |
| FY 2024 | $98.3M | $618.3M | — | — | $149.7M | -$69.2M |
| FY 2023 | $133.6M | $608.0M | — | — | $113.9M | -$142.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
TWST // BETA 0.98